Targeting Fibroblast Growth Factor Receptor News Today : Breaking News, Live Updates & Top Stories | Vimarsana

March 2021
Fusion - Next Generation TATs for Precision Oncology
Targeted Alpha Therapies (TATs) deliver radiation directly to cancer cells using a precision medicine approach (theranostics)
■ Fusion can create TATs from wide range of targeting molecules
(antibodies, proteins, small molecules)
We are expanding our pipeline by acquiring a small molecule that binds NTSR1; a validated cancer marker found on multiple cancer types notably pancreatic and colorectal cancers
■ Clinical imaging data show uptake of diagnostic form in
pancreatic and CRC cancer patients
■ Preclinical therapy data with 225Ac (alpha emitter) show
single dose tumor kill - high potency
This first in class radiopharmaceutical augments our programs: ....

United States , Radiopharma Optimizationpreclinical Developmentphase , Isotopethe Chelateproprietary , Fusion Pharmaceuticals Inc , Decision Resources Group , American Cancer Society , Alpha Therapies , Targeting Fibroblast Growth Factor Receptor , Experience Linking Alpha Emitting Isotopes , Supply Chain Expertiseleadership Position , Establishing Fusion , Emitter Multiple Mechanisms Show Enhanced Killing , Resources Group , Cancer Society , Bladder Cancers Expressing , Optimizationpreclinical Developmentphase , All Rights , Fusion Pharmaceuticals Inc Stock Exchange , Press Release , Precision Fusn , ஒன்றுபட்டது மாநிலங்களில் , இணைவு மருந்துகள் இன்க் , முடிவு வளங்கள் குழு , அமெரிக்கன் புற்றுநோய் சமூகம் , ஆல்பா சிகிச்சைகள் , அனுபவம் இணைத்தல் ஆல்பா உமிழ்வு ஐசோடோப்புகள் ,